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Abstract
Bone regeneration is a complex, well-orchestrated
physiological process of bone formation, which can be
seen during normal fracture healing, and is involved in
continuous remodelling throughout adult life. However,
there are complex clinical conditions in which bone
regeneration is required in large quantity, such as for
skeletal reconstruction of large bone defects created by
trauma, infection, tumour resection and skeletal
abnormalities, or cases in which the regenerative
process is compromised, including avascular necrosis,
atrophic non-unions and osteoporosis. Currently, there
is a plethora of different strategies to augment the
impaired or ‘insufficient’ bone-regeneration process,
including the ‘gold standard’ autologous bone graft,
free fibula vascularised graft, allograft implantation, and
use of growth factors, osteoconductive scaffolds,
osteoprogenitor cells and distraction osteogenesis.
Improved ‘local’ strategies in terms of tissue engineering
and gene therapy, or even ‘systemic’ enhancement of
bone repair, are under intense investigation, in an effort
to overcome the limitations of the current methods, to
produce bone-graft substitutes with biomechanical
properties that are as identical to normal bone as
possible, to accelerate the overall regeneration process,
or even to address systemic conditions, such as skeletal
disorders and osteoporosis.
Introduction
Bone possesses the intrinsic capacity for regeneration as
part of the repair process in response to injury, as well as
during skeletal development or continuous remodelling
throughout adult life [1,2]. Bone regeneration is com-
prised of a well-orchestrated series of biological events of
bone induction and conduction, involving a number of
cell types and intracellular and extracellular molecular-
signalling pathways, with a definable temporal and spatial
sequence, in an effort to optimise skeletal repair and
restore skeletal function [2,3]. In the clinical setting, the
most common form of bone regeneration is fracture
healing, during which the pathway of normal fetal skele-
togenesis, including intramembranous and endochondral
ossification, is recapitulated [4]. Unlike in other tissues,
the majority of bony injuries (fractures) heal without the
formation of scar tissue, and bone is regenerated with its
pre-existing properties largely restored, and with the
newly formed bone being eventually indistinguishable
from the adjacent uninjured bone [2]. However, there are
cases of fracture healing in which bone regeneration is
impaired, with, for example, up to 13% of fractures
occurring in the tibia being associated with delayed
union or fracture non-union [5]. In addition, there are
other conditions in orthopaedic surgery and in oral and
maxillofacial surgery in which bone regeneration is
required in large quantity (beyond the normal potential
for self-healing), such as for skeletal reconstruction of
large bone defects created by trauma, infection, tumour
resection and skeletal abnormalities, or cases in which
the regenerative process is compromised, including avas-
cular necrosis and osteoporosis.
Current clinical approaches to enhance bone
regeneration
For all the aforementioned cases in which the normal
process of bone regeneration is either impaired or simply
insufficient, there are currently a number of treatment
methods available in the surgeon’s armamentarium,
which can be used either alone or in combination for the
enhancement or management of these complex clinical
situations, which can often be recalcitrant to treatment,
representing a medical and socioeconomic challenge.
Standard approaches widely used in clinical practice to
stimulate or augment bone regeneration include distrac-
tion osteogenesis and bone transport [6,7], and the use of
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autologous bone grafts, allografts, and bone-graft substi-
tutes or growth factors [8,9]. An alternative method for
bone regeneration and reconstruction of long-bone
defects is a two-stage procedure, known as the Masquelet
technique. It is based on the concept of a “biological”
membrane, which is induced after application of a
cement spacer at the first stage and acts as a ‘chamber’
for the insertion of non-vascularised autograft at the sec-
ond stage [10]. There are even non-invasive methods of
biophysical stimulation, such as low-intensity pulsed
ultrasound (LIPUS) and pulsed electromagnetic fields
(PEMF) [11-13], which are used as adjuncts to enhance
bone regeneration.
During distraction osteogenesis and bone transport,
bone regeneration is induced between the gradually dis-
tracted osseous surfaces. A variety of methods are cur-
rently used to treat bone loss or limb-length
discrepancies and deformities, including external fixators
and the Ilizarov technique [6,7], combined unreamed
intramedullary nails with external monorail distraction
devices [14], or intramedullary lengthening devices [15].
However, these methods are technically demanding and
have several disadvantages, including associated compli-
cations, requirement for lengthy treatment for both the
distraction (1 mm per day) and the consolidation period
(usually twice the distraction phase), and effects on the
patient’s psychology and well-being [6,7].
Bone grafting is a commonly performed surgical proce-
dure to augment bone regeneration in a variety of ortho-
paedic and maxillofacial procedures, with autologous bone
being considered as the ‘gold standard’ bone-grafting
material, as it combines all properties required in a bone-
graft material: osteoinduction (bone morphogenetic pro-
teins (BMPs) and other growth factors), osteogenesis
(osteoprogenitor cells) and osteoconduction (scaffold)
[16]. It can also be harvested as a tricortical graft for struc-
tural support [16], or as a vascularised bone graft for
restoration of large bone defects [17] or avascular necrosis
[18]. A variety of sites can be used for bone-graft harvest-
ing, with the anterior and posterior iliac crests of the pelvis
being the commonly used donor sites. Recently, with the
development of a new reaming system, the reamer-irriga-
tor-aspirator (RIA), initially developed to minimise the
adverse effects of reaming during nailing of long-bone
fractures, the intramedullary canal of long bones has been
used as an alternative harvesting site, providing a large
volume of autologous bone graft [19]. Furthermore,
because it is the patient’s own tissue, autologous bone is
histocompatible and non-immunogenic, reducing to a
minimum the likelihood of immunoreactions and trans-
mission of infections. Nevertheless, harvesting requires an
additional surgical procedure, with well-documented com-
plications and discomfort for the patient, and has the
additional disadvantages of quantity restrictions and sub-
stantial costs [20-22].
An alternative is allogeneic bone grafting, obtained from
human cadavers or living donors, which bypasses the pro-
blems associated with harvesting and quantity of graft
material. Allogeneic bone is available in many prepara-
tions, including demineralised bone matrix (DBM), mor-
cellised and cancellous chips, corticocancellous and
cortical grafts, and osteochondral and whole-bone seg-
ments, depending on the recipient site requirements.
Their biological properties vary, but overall, they possess
reduced osteoinductive properties and no cellular compo-
nent, because donor grafts are devitalised via irradiation or
freeze-drying processing [23]. There are issues of immu-
nogenicity and rejection reactions, possibility of infection
transmission, and cost [8,23].
Bone-graft substitutes have also been developed as alter-
natives to autologous or allogeneic bone grafts. They con-
sist of scaffolds made of synthetic or natural biomaterials
that promote the migration, proliferation and differentia-
tion of bone cells for bone regeneration. A wide range of
biomaterials and synthetic bone substitutes are currently
used as scaffolds, including collagen, hydroxyapatite (HA),
b-tricalcium phosphate (b-TCP) and calcium-phosphate
cements, and glass ceramics [8,23], and the research into
this field is ongoing. Especially for reconstruction of large
bone defects, for which there is a need for a substantial
structural scaffold, an alternative to massive cortical auto-
or allografts is the use of cylindrical metallic or titanium
mesh cages as a scaffold combined with cancellous bone
allograft, DBM or autologous bone [24,25].
Limitations of current strategies to enhance bone
regeneration
Most of the current strategies for bone regeneration exhi-
bit relatively satisfactory results. However, there are asso-
ciated drawbacks and limitations to their use and
availability, and even controversial reports about their effi-
cacy and cost-effectiveness. Furthermore, at present there
are no heterologous or synthetic bone substitutes available
that have superior or even the same biological or mechani-
cal properties compared with bone. Therefore, there is a
necessity to develop novel treatments as alternatives or
adjuncts to the standard methods used for bone regenera-
tion, in an effort to overcome these limitations, which has
been a goal for many decades. Even back in the 1950s,
Professor Sir Charnley, a pioneer British orthopaedic sur-
geon, stated that ‘practically all classical operations of sur-
gery have now been explored, and unless some
revolutionary discovery is made which will put the control
of osteogenesis in the surgeon’s power, no great advance is
likely to come from modification of their detail’ [26].
Since then, our understanding of bone regeneration at
the cellular and molecular level has advanced enormously,
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cess, such as quantitative three-dimensional microcom-
puted tomography analyses, finite element modelling, and
nanotechnology have been developed to further evaluate
the mechanical properties of bone regenerate at the micro-
scopic level. In addition, advances made in cellular and
molecular biology have allowed detailed histological ana-
lyses, in vitro and in vivo characterisation of bone-forming
cells, identification of transcriptional and translational pro-
files of the genes and proteins involved in the process of
bone regeneration and fracture repair, and development of
transgenic animals to explore the role of a number of
genes expressed during bone repair, and their temporal
and tissue-specific expression patterns [27]. With the
ongoing research in all related fields, novel therapies have
been used as adjuncts or alternatives to traditional bone-
regeneration methods. Nevertheless, the basic concept for
managing all clinical situations requiring bone regenera-
tion, particularly the complex and recalcitrant cases,
remains the same, and must be applied. Treatment strate-
gies should aim to address all (or those that require
enhancement) prerequisites for optimal bone healing,
including osteoconductive matrices, osteoinductive factors,
osteogenic cells and mechanical stability, following
the ‘diamond concept’ suggested for fracture healing
(Figure 1) [28].
BMPs and other growth factors
With improved understanding of fracture healing and
bone regeneration at the molecular level [29], a number
of key molecules that regulate this complex physiologi-
cal process have been identified, and are already in clini-
cal use or under investigation to enhance bone repair.
Of these molecules, BMPs have been the most exten-
sively studied, as they are potent osteoinductive factors.
They induce the mitogenesis of mesenchymal stem cells
(MSCs) and other osteoprogenitors, and their differen-
tiation towards osteoblasts. Since the discovery of BMPs,
a number of experimental and clinical trials have sup-
ported the safety and efficacy of their use as osteoinduc-
tive bone-graft substitutes for bone regeneration. With
the use of recombinant DNA technology, BMP-2 and
BMP-7 have been licensed for clinical use since 2002
and 2001 respectively [30]. These two molecules have
been used in a variety of clinical conditions including
non-union, open fractures, joint fusions, aseptic bone
necrosis and critical bone defects [9]. Extensive research
is ongoing to develop injectable formulations for mini-
mally invasive application, and/or novel carriers for pro-
longed and targeted local delivery [31].
Other growth factors besides BMPs that have been
implicated during bone regeneration, with different
functions in terms of cell proliferation, chemotaxis and
angiogenesis, are also being investigated or are currently
being used to augment bone repair [32,33], including
platelet-derived growth factor, transforming growth fac-
tor-b, insulin-like growth factor-1, vascular endothelial
growth factor and fibroblast growth factor, among
others [29]. These have been used either alone or in
combinations in a number of in vitro and in vivo stu-
dies, with controversial results [32,33]. One current
approach to enhance bone regeneration and soft-tissue
healing by local application of growth factors is the use
of platelet-rich plasma, a volume of the plasma fraction
of autologous blood with platelet concentrations above
baseline, which is rich in many of the aforementioned
molecules [34].
’Orthobiologics’ and the overall concept to stimulate
the local ‘biology’ by applying growth factors (especially
BMPs, because these are the most potent osteoinductive
molecules) could be advantageous for bone regeneration
or even for acceleration of normal bone healing to
reduce the length of fracture treatment. Their clinical
use, either alone or combined with bone grafts, is con-
stantly increasing. However, there are several issues
about their use, including safety (because of the supra-
physiological concentrations of growth factors needed to
obtain the desired osteoinductive effects), the high cost
of treatment, and more importantly, the potential for
ectopic bone formation [35].
Currently BMPs are also being used in bone-tissue
engineering, but several issues need to be further exam-
ined, such as optimum dosage and provision of a sus-
tained, biologically appropriate concentration at the site
of bone regeneration, and the use of a ‘cocktail’ of other
growth factors that have shown significant promising
results in preclinical and early clinical investigation [32]
or even the use of inhibitory molecules in an effort to
mimic the endogenous ‘normal’ growth-factor produc-
tion. Nanoparticle technology seems to be a promising
approach for optimum growth-factor delivery in the
future of bone-tissue engineering [36]. Nevertheless,
owing to gaps in the current understanding of these fac-
tors, it has not been possible to reproduce in vivo bone
regeneration in the laboratory.
MSCs
An adequate supply of cells (MSCs and osteoprogeni-
tors) is important for efficient bone regeneration. The
current approach of delivering osteogenic cells directly
to the regeneration site includes use of bone-marrow
aspirate from the iliac crest, which also contains growth
factors. It is a minimally invasive procedure to enhance
bone repair, and produces satisfactory results [37]. How-
ever, the concentration and quality of MSCs may vary
significantly, depending on the individual (especially in
older people) [38,39], the aspiration sites and techniques
used [39], and whether further concentration of the
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aspiration concentrate (BMAC) is considered to be an
effective product to augment bone grafting and support
bone regeneration [40,41]. Overall, however, there are
significant ongoing issues with quality control with
respect to delivering the requisite number of MSCs/
osteoprogenitors to effect adequate repair responses
[40].
Issues of quantity and alternative sources of MSCs are
being extensively investigated. Novel approaches in terms
of cell harvesting, in vitro expansion and subsequent
implantation are promising [42-44], because in vitro
expansion can generate a large number of progenitor cells.
However, such techniques add substantial cost and risks
(such as contamination with bacteria or viruses), may
reduce the proliferative capacity of the cells and are time-
consuming requiring two-stage surgery [45]. This strategy
is already applied for cartilage regeneration [46]. Alterna-
tive sources of cells, which are less invasive, such as per-
ipheral blood [47] and mesenchymal progenitor cells from
fat [48], muscle, or even traumatised muscle tissue after
debridement [49], are also under extensive research. How-
ever, the utility of fat-derived MSCs for bone-regeneration
applications is debatable, with some studies showing them
to be inferior to bone-marrow-derived MSCs in animal
models [50,51], and the evidence for a clinically relevant
Figure 1 Male patient 19 years of age with infected non-union after intramedullary nailing of an open tibial fracture. (A).
Anteroposterior (AP) and lateral X-rays of the tibia illustrating osteolysis (white arrow) secondary to infection. The patient underwent removal of
the nail, extensive debridement and a two-staged reconstruction of the bone defect, using the induced membrane technique for bone
regeneration (the Masquelet technique). (B) Intraoperative pictures showing: (1) a 60 mm defect of the tibia (black arrow) at the second stage of
the procedure; (2) adequate mechanical stability was provided with internal fixation (locking plate) bridging the defect, while the length was
maintained (black arrow); (3) maximum biological stimulation was provided using autologous bone graft harvested from the femoral canal (black
arrow, right), bone-marrow mesenchymal stem cells (broken arrow, left) and the osteoinductive factor bone morphogenetic protein-7 (centre);
(4) the graft was placed to fill the bone defect (black arrow). (C) Intraoperative fluoroscopic images showing the bone defect after fixation. (D)
Postoperative AP and lateral X-rays at 3 months, showing the evolution of the bone regeneration process with satisfactory incorporation and
mineralisation of the graft (photographs courtesy of PVG).
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remains very contentious [52].
It is fair to say that the role of MSCs in fracture repair
is still in its infancy, largely due to a lack of studies into
the biology of MSCs in vivo in the fracture environment.
This to a large extent relates to the historical perceived
rarity of ‘in vivo MSCs’ and also to a lack of knowledge
about in vivo phenotypes. The in vivo phenotype of
bone-marrow MSCs has been recently reported [53]
and, even more recently, it has been shown that this
population was actually fairly abundant in vivo in nor-
mal and pathological bone [54]. This knowledge opens
up novel approaches for the characterisation and mole-
cular profiling of MSCs in vivo i nt h ef r a c t u r ee n v i r o n -
ment. This could be used to ultimately improve
outcomes of fracture non-union based on the biology of
these key MSC reparative cells.
Scaffolds and bone substitutes
Although they lack osteoinductive or osteogenic proper-
ties, synthetic bone substitutes and biomaterials are
already widely used in clinical practice for osteoconduc-
tion. DBM and collagen are biomaterials, used mainly as
bone-graft extenders, as they provide minimal structural
support [8]. A large number of synthetic bone substitutes
are currently available, such as HA, b-TCP and calcium-
phosphate cements, and glass ceramics [8,23]. These are
being used as adjuncts or alternatives to autologous bone
grafts, as they promote the migration, proliferation and
differentiation of bone cells for bone regeneration. Espe-
cially for regeneration of large bone defects, where the
requirements for grafting material are substantial, these
synthetics can be used in combination with autologous
bone graft, growth factors or cells [8]. Furthermore, there
are also non-biological osteoconductive substrates, such
as fabricated biocompatible metals (for example, porous
tantalum) that offer the potential for absolute control of
the final structure without any immunogenicity [8].
Research is ongoing to improve the mechanical prop-
erties and biocompatibility of scaffolds, to promote
osteoblast adhesion, growth and differentiation, and t0
allow vascular ingrowth and bone-tissue formation.
Improved biodegradable and bioactive three-dimensional
porous scaffolds [55] are being investigated, as well as
novel approaches using nanotechnology, such as mag-
netic biohybrid porous scaffolds acting as a crosslinking
agent for collagen for bone regeneration guided by an
external magnetic field [56], or injectable scaffolds for
easier application [57].
Tissue engineering
The tissue-engineering approach is a promising strategy
added in the field of bone regenerative medicine, which
aims to generate new, cell-driven, functional tissues,
rather than just to implant non-living scaffolds [58].
This alternative treatment of conditions requiring bone
regeneration could overcome the limitations of current
therapies, by combining the principles of orthopaedic
surgery with knowledge from biology, physics, materials
science and engineering, and its clinical application
offers great potential [58,59]. In essence, bone-tissue
engineering combines progenitor cells, such as MSCs
(native or expanded) or mature cells (for osteogenesis)
seeded in biocompatible scaffolds and ideally in three-
dimensional tissue-like structures (for osteoconduction
and vascular ingrowth), with appropriate growth factors
(for osteoinduction), in order to generate and maintain
bone [60]. The need for such improved composite grafts
is obvious, especially for the management of large bone
defects, for which the requirements for grafting material
are substantial [8]. At present, composite grafts that are
available include bone synthetic or bioabsorbable scaf-
folds seeded with bone-marrow aspirate or growth fac-
tors (BMPs), providing a competitive alternative to
autologous bone graft [8].
Several major technical advances have been achieved in
t h ef i e l do fb o n e - t i s s u ee n g i n e e r i n gd u r i n gt h ep a s td e c -
ade, especially with the increased understanding of bone
healing at the molecular and cellular level, allowing the
conduction of numerous animal studies and of the first
pilot clinical studies using tissue-engineered constructs for
local bone regeneration. To date, seven human studies
have been conducted using culture-expanded, non-geneti-
cally modified MSCs for regeneration of bone defects: two
studies reporting on long bones and five on maxillofacial
conditions [61]. Even though they are rather heteroge-
neous studies and it is difficult to draw conclusive evi-
dence from them, bone apposition by the grafted MSCs
was seen, but it was not sufficient to bridge large bone
defects. Furthermore, the tissue-engineering approach has
been used to accelerate the fracture-healing process or to
augment the bone-prosthesis interface and prevent aseptic
loosening in total joint arthroplasty, with promising results
regarding its efficacy and safety [62,63].
Recently, an animal study has shown the potential for
prefabrication of vascularised bioartificial bone grafts in
vivo using b-TCP scaffolds intraoperatively filled with
autogenous bone marrow for cell loading, and implanted
into the latissimus dorsi muscle for potential application
at a later stage for segmental bone reconstruction, intro-
ducing the principles of bone transplantation with mini-
mal donor-site morbidity and no quantity restrictions [64].
Overall, bone-tissue engineering is in its infancy, and
there are many issues of efficacy, safety and cost to be
addressed before general clinical application can be
achieved. Cultured-expanded cells may have mutations or
epigenetic changes that could confer a tumour-forming
potential [44]. However, in vitro and in vivo evidence
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No cases of tumour transformation were reported in 41
patients (45 joints) after autologous bone-marrow-derived
MSC transplantation for cartilage repair, who were fol-
lowed for up to 11 years and 5 months [46]. Another
important issue is the difficulty of achieving an effective
and high-density cell population within three-dimensional
biodegradable scaffolds [66]. Consequently, numerous
bioreactor technologies have been investigated, and many
others should be developed [67]. Their degradation prop-
erties should also preserve the health of local tissues and
the continuous remodelling of bone [44]. Three-dimen-
sional porous scaffolds with specific architectures at the
nano, micro and macro scale for optimum surface porosity
and chemistry, which enhance cellular attachment, migra-
tion, proliferation and differentiation, are undergoing a
continuous evaluation process.
Gene therapy
Another promising method of growth-factor delivery in
the field of bone-tissue engineering is the application of
gene therapy [68,69]. This involves the transfer of genetic
material into the genome of the target cell, allowing
expression of bioactive factors from the cells themselves
for a prolonged time. Gene transfer can be performed
using a viral (transfection) or a non-viral (transduction)
vector, and by either an in vivo or ex vivo gene-transfer
strategy. With the in vivo method, which is technically
relatively easier, the genetic material is transferred
directly into the host; however, there are safety concerns
with this approach. The indirect ex vivo technique
requires the collection of cells by tissue harvest, and their
genetic modification in vitro before transfer back into the
host. Although technically more demanding, it is a safer
method, allowing testing of the cells for any abnormal
behaviour before reimplantation, and selection of those
with the highest gene expression [69].
Besides the issues of cost, efficacy and biological safety
that need to be answered before this strategy of genetic
manipulation is applied in humans, delivery of growth
factors, particularly BMPs, using gene therapy for bone
regeneration has already produced promising results in
animal studies [70,71].
Mechanical stability and the role of mechanical
stimulation in bone regeneration
In addition to the intrinsic potential of bone to regener-
ate and to the aforementioned methods used to enhance
bone regeneration, adequate mechanical stability by var-
ious means of stabilisation and use of fixation devices is
also an important element for optimal bone repair, espe-
cially in challenging cases involving large bone defects
or impaired bone healing. The mechanical environment
constitutes the fourth factor of the ‘diamond concept’ of
fracture healing, along with osteoconductive scaffolds,
growth factors and osteogenic cells, interacting during
the repair process [28].
During bone regeneration, intermediate tissues, such as
fibrous connective tissue, cartilage and woven bone, pre-
cede final bone formation, providing initial mechanical
stability and a scaffold for tissue differentiation. The
mechanical loading affects the regeneration process, with
different stress distribution favouring or inhibiting differ-
entiation of particular tissue phenotypes [72]. High shear
strain and fluid flows are thought to stimulate formation
of fibrous connective tissue, whereas lower levels stimu-
late formation of cartilage, and even lower levels favour
ossification [72].
The interfragmentary strain concept of Perren has been
used to describe the different patterns of bone repair (pri-
mary or secondary fracture healing), suggesting that the
strain that causes healthy bone to fail is the upper limit
that can be tolerated for the regenerating tissue [73]. Since
then, extensive research on this field has further refined
the effects of mechanical stability and mechanical stimula-
tion on bone regeneration and fracture healing [74].
Numerous in vivo studies have shown contradictory
results regarding the contribution of strain and mechanical
stimulation, in terms of compression or distraction, in
bone formation during fracture healing. In early fracture
healing, mechanical stimulation seems to enhance callus
formation, but the amount of callus formation does not
correspond to stiffness [74]. During the initial stages of
bone healing, a less rigid mechanical environment resulted
in a prolonged chondral bone regeneration phase, whereas
the process of intramembranous ossification appeared to
be independent of mechanical stability [75]. By contrast, a
more rigid mechanical environment resulted in a smaller
callus and a reduced fibrous-tissue component [76]. For
later stages of bone regeneration, lower mechanical stabi-
lity was found to inhibit callus bridging and stiffness [74].
Finally, in vitro s t u d i e sh a v ea l s os h o w nt h er o l eo ft h e
mechanical environment on different cell types involved in
bone regeneration. It has been demonstrated using cell-
culture systems that the different cellular responses in
terms of proliferation and differentiation after mechanical
stimulation depend on the strain magnitude and the cell
phenotype [74].
Mechanical stability is also important for local vascu-
larisation and angiogenesis during bone regeneration. In
an inv i v ostudy, it was shown that smaller interfragmen-
tary movements led to the formation of a greater number
of vessels within the callus, particularly in areas close to
the periosteum, compared with larger movements [77],
whereas increased interfragmentary shear was associated
with reduced vascularisation with a higher amount of
fibrous-tissue formation and a lower percentage of
mineralised bone during early bone healing [78].
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ment throughout the bone-regeneration process is also
essential when additional methods are being used to
enhance bone repair [28,79]. Optimal instrumentation
with minimal disruption of the local blood supply is
required to supplement and protect the mechanical prop-
erties of the implanted grafts or scaffolds to allow incor-
poration, vascularisation and subsequent remodelling [79].
Systemic enhancement of bone regeneration
As an alternative to local augmentation of the bone-regen-
eration process, the use of systemic agents, including
growth hormone (GH) [80] and parathyroid hormone
(PTH) [81] is also under extensive research. Current evi-
dence suggests a positive role for GH in fracture healing,
but there are issues about its safety profile and optimal
dose, when systemically administered to enhance bone
repair [80]. There are also numerous animal studies and
clinical trials showing that intermittent PTH administra-
tion induces both cancellous and cortical bone regenera-
tion, enhances bone mass, and increases mechanical bone
strength and bone-mineral density, with a relatively satis-
factory safety profile [81,82]. Currently, two PTH analo-
gues, PTH 1-34 (or teriparitide) and PTH 1-84, are already
used in clinical practice as anabolic agents for the treat-
ment of osteoporosis [81,83], and research is being carried
out into their off-label use as bone-forming agents in com-
plex conditions requiring enhancement of bone repair,
such as complicated fractures and non-unions.
In addition to the anabolic agents for bone regeneration,
current antiresorptive therapies that are already in clinical
use for the management of osteoporosis could be used to
increase bone-mineral density during bone regeneration
and remodelling by reducing bone resorption. Biphospho-
nates, known to reduce the recruitment and activity of
osteoclasts and increase their apoptosis, and strontium
ranelate, known to inhibit bone resorption and stimulate
bone formation, could be beneficial adjuncts to bone
repair by altering bone turnover [84]. In addition, a new
pharmaceutical agent called denosumab, which is a fully
human monoclonal antibody designed to target receptor
activator of nuclear factor-B ligand (RANKL), a protein
that selectively inhibits osteoclastogenesis, might not only
decrease bone turnover and increase bone-mineral density
in osteoporosis, but also indirectly improve bone regenera-
tion in other conditions requiring enhancement [85].
Recently, another signalling pathway, the Wnt path-
way, was found to play a role in bone regeneration [86].
Impaired Wnt signalling is associated with osteogenic
pathologies, such as osteoporosis and osteopenia. Thus,
novel strategies that systemically induce the Wnt signal-
ling pathway or inhibit its antagonists, such as scleros-
tin, can improve bone regeneration. However, there are
concerns about carcinogenesis [87].
Another approach for systemic enhancement of bone
regeneration is the use of agonists of the prostaglandin
receptors EP2 and EP4, which were found to be skele-
tally anabolic at cortical and cancellous sites. Promising
results have been seen in animal models, without
adverse effects, and therefore these receptors may repre-
sent novel anabolic agents for the treatment of osteo-
porosis and for augmentation of bone healing [27].
Finally, new treatments for systemic augmentation of
bone regeneration may come to light while researchers are
trying to elucidate the alterations seen at the cellular and
molecular level in conditions with increased bone forma-
tion capacity. Fibrodysplasia ossificans progressiva, a rare
genetic disorder, is an example of how an abnormal meta-
bolic condition can be viewed as evidence for systemic
regeneration of large amounts of bone secondary to altera-
tions within the BMP signalling pathway [88], and may
indicate unique treatment potentials.
Conclusions
There are several clinical conditions that require enhance-
ment of bone regeneration either locally or systemically,
and various methods are currently used to augment or
accelerate bone repair, depending on the healing potential
and the specific requirements of each case. Knowledge of
bone biology has vastly expanded with the increased
understanding at the molecular level, resulting in develop-
ment of many new treatment methods, with many others
(or improvements to current ones) anticipated in the years
to come. However, there are still gaps; in particular, there
is still surprisingly little information available about the
cellular basis for MSC-mediated fracture repair and bone
regeneration in vivo in humans. Further understanding in
this area could be the key to an improved and integrated
strategy for skeletal repair.
In the future, control of bone regeneration with strate-
gies that mimic the normal cascade of bone formation
will offer successful management of conditions requiring
enhancement of bone regeneration, and reduce their
morbidity and cost in the long term. Research is ongoing
within all relevant fields, and it is hoped that many bone-
disease processes secondary to trauma, bone resection
due to ablative surgery, ageing, and metabolic or genetic
skeletal disorders will be successfully treated with novel
bone-regeneration protocols that may address both local
and systemic enhancement to optimise outcome.
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